Arla Food Ingredients gets ESFA safety nod for novel Bovine Milk Osteopontin ingredient

By Katy Askew

- Last updated on GMT

Arla's ingredient will allow formula makers to deliver similar levels of OPN to those found in breast milk / Pic: iStock
Arla's ingredient will allow formula makers to deliver similar levels of OPN to those found in breast milk / Pic: iStock

Related tags Arla foods ingredients Infant formula Efsa

Arla Foods Ingredients has secured Novel Food approval for Lacprodan OPN-10, an ingredient derived from Bovine Milk Osteopontin (OPN).

The European Food Safety Authority (EFSA) has published an opinion that OPN is safe for use in infant formula, follow-on formula and ready-to-eat dairy-based meals for children.

When the full Novel Foods process is complete, Lacprodan OPN-10 will be Arla Foods Ingredients’ first infant nutrition product approved under the Novel Food Regulation. Products containing Lacprodan OPN-10 will be authorised for sale in Europe towards the end of 2022 or by early 2023, the company predicted.

“We’re delighted by this decision, which is a significant step towards achieving Novel Food approval. It’s a strong signal of trustworthiness in this new ingredient for infant milk formula, and opens up new opportunities for formula manufacturers,”​ Anders Steen Jørgensen, Director Paediatric at Arla Foods Ingredients said.

Osteopontin is a whey protein, which is a heavily phosphorylated, acidic glycoprotein with strong calcium-binding properties. Significant amounts of this protein have been identified in human milk, while smaller quantities are present in bovine milk. This means that – to date – infant formulas have had lower osteopontin content than human breast milk.

The EFSA opinion considered the use of OPN in infant formula, follow-on-formula and ready to eat children's meals at a maximum concentration of 151mg/l. This is around a ten-fold higher concentration than OPN naturally found in cow’s milk and infant formula already on the market, the food safety authority noted. The intended use levels of the Novel Food would provide OPN at a concentration ‘within the range of human milk’ OPN.

“The Panel concludes that the NF is safe under the proposed conditions of use,”​ EFSA stated.

EFSA approval is an important milestone within the Novel Foods regulation as it helps inform the final decision which is issued by the European Commission.

With regulatory approval on the horizon, Arla Food Ingredients said it will be able to help infant formula manufacturers to develop products containing osteopontin in its ‘purest form to date’. Arla Foods Ingredients already holds several patents for the production and application of osteopontin.

“This is the result of more than five years of hard work from our R&D department, Early Life Nutrition Science teams and regulatory teams. Lacprodan OPN-10 is a fantastic addition to our infant nutrition portfolio and continues our record of being first to market with products in this sector,”​ Jørgensen added.

Related news

Show more

Related products

show more

Future Food-Tech London - Download Summit Brochure

Future Food-Tech London - Download Summit Brochure

Content provided by Future Food-Tech London, September 28-29, 2023 | 01-Aug-2023 | Product Brochure

Future Food-Tech's European flagship brings together 800+ leaders from food brands, ingredient providers, pioneering entrepreneurs, and investors,...

From Pod to Plate: Unlock the Power of Pea Protein

From Pod to Plate: Unlock the Power of Pea Protein

Content provided by ADM | 12-Jul-2023 | Case Study

ADM is expanding our world-class textured pea protein portfolio with our newest solutions, AccelFlex™ TS P80 and AccelFlex™ TS P65. Both feature a clean,...

The latest trends in plant-based meat alternatives

The latest trends in plant-based meat alternatives

Content provided by ADM | 10-Jul-2023 | Infographic

Today’s consumers are increasingly taking a proactive approach to their health and wellness, seeking expanded protein choices to diversify their diets....

Related suppliers

Follow us


View more